PrecisionPhage to Join Leading AMR Conference
PrecisionPhage is excited to announce its participation in the upcoming AMR Conference 2026 in Basel, Switzerland, one of Europe’s premier gathering focused on antimicrobial resistance (AMR).
“AMR is a global crisis and we believe phage and computational solutions utilised in infection treatment and biosafety present one of the most promising paths forward,” said Matti Jalasvuori, CEO of PrecisionPhage. “Our presence at AMR 2026 underlines our commitment to making an impact.”
Visitors and partners are invited to meet our team at booth #23 and hear how PrecisionPhage continues to build the ecosystem for effective phage utilisation and state-of-the-art biosafety solutions.
About PrecisionPhage
Founded in 2022 and rooted in robust academic research, PrecisionPhage is a Finland-based biotech company building integrated pipelines for phage isolation, bioinformatics analysis and licensing of bacteriophages. With collaborations worldwide spanning from pre-clinical development to applied industries, the company is committed to making phage technology accessible and impactful globally.
